title: [Spontaneous enterocutaneous and rectovaginal fistula: potential complications during therapy with anti-angiogenic drugs in renal cancer].
abstract: We present two cases of enterovaginal and enterocutaneous fistulae associated to treatment with pazopanib, which is an angiogenesis inhibitor for the treatment of metastatic renal cancer. The times from drug administration and the first appearance of a fistula were 6 and 16 months, respectively. None of the cases had a history of surgery or radiotherapy in the area where the complication was observed. Enterovaginal and enterocutaneous fistula represent less than 1% of all published complications caused by the use of antiangiogenic drugs. However, they must be taken into account as the reported mortality rate is close to 30%. Given its low incidence, we believe that sharing this data is a great way to help specialists who have to treat these patients to take the necessary precautions and decide on an adequate approach.
authors.affiliation: Servicio de Urología y Servicio de Oncología. Fundación IVO. Valencia, España.
authors.forename: Sebastián
authors.initials: S
authors.lastname: Valverde-Martínez
authors.affiliation: Servicio de Urología y Servicio de Oncología. Fundación IVO. Valencia, España.
authors.forename: Miguel
authors.initials: M
authors.lastname: Ramírez-Backhaus
authors.affiliation: Servicio de Urología y Servicio de Oncología. Fundación IVO. Valencia, España.
authors.forename: José
authors.initials: J
authors.lastname: Rubio-Briones
authors.affiliation: Servicio de Urología y Servicio de Oncología. Fundación IVO. Valencia, España.
authors.forename: Miguel Ángel
authors.initials: MÁ
authors.lastname: Climent-Durán
authors.affiliation: Servicio de Urología y Servicio de Oncología. Fundación IVO. Valencia, España.
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Iborra
authors.affiliation: Servicio de Urología y Servicio de Oncología. Fundación IVO. Valencia, España.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Solsona-Narbón
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007191:Indazoles; D007412:Intestinal Fistula / Q000139:chemically induced*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D012006:Rectovaginal Fistula / Q000139:chemically induced*; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib